EMA Application withdrawn: Xiidra (Lifitegrast) — Novartis Europharm Limited

View source ↗

Summary

EMA indicates withdrawal of the application for Xiidra (lifitegrast) by Novartis Europharm Limited for dry eye syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Syndrome

Drugs mentioned

• Xiidra (Lifitegrast)

Snippet

Status: Application withdrawn. Therapeutic area: Dry Eye Syndromes. MAH: Novartis Europharm Limited